M.D. Anderson Cancer Center
Open enrollment with an early-phase pipeline tilt
According to ClinicalTrials.gov-derived indexes, M.D. Anderson Cancer Center sits in the top decile of US sponsors by registered trial count (#3 of 15,751 sponsors by registered trial count).
M.D. Anderson Cancer Center: 2,692 sponsored US clinical trials, 549 recruiting.
M.D. Anderson Cancer Center sponsors 2,692 registered US clinical trials on ClinicalTrials.gov, 549 of them currently recruiting, and 1,201 completed. 124 of these trials are in Phase 3-4 (later-stage) and 1,719 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Hematopoietic and Lymphoid Cell Neoplasm, with 44 trials.
Top-decile sponsor footprint
M.D. Anderson Cancer Center ranks in the top decile of sponsors by registered trial count (#3 of 15,751 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Open and recent trials
2,692 total, page 48 of 54
Injection Methods in Finding the Sentinel Lymph Node During Lymphatic Mapping and Sentinel Lymph Node Biopsy in Patients With Invasive Breast Cancer
NCT00438477
Markers of Response to Intravesical Bladder Cancer Therapy
NCT01007058
Subcutaneous Olanzapine for Hyperactive or Mixed Delirium
NCT00512291
CFAR Study in Patients With Chronic Lymphocytic Leukemia
NCT00525603
Ph II Study of Azacitidine in Myelofibrosis
NCT00569660
Evaluation of the Safety and Efficacy of Nipent, Cytoxan, and Rituxan
NCT00496873
Neoadjuvant Hormones + Docetaxel in Node-Positive Prostate Cancer
NCT01076335
Thymoglobulin and Cyclosporine in Patients With Aplastic Anemia or Myelodysplastic Syndrome
NCT00806598
Azacytidine and Valproic Acid in Patients With Advanced Cancers
NCT00496444
Phase I Trial of ZIO-101 in Patients With Solid Tumors
NCT00509782
Pegasys® in Patients With Myeloproliferative Diseases
NCT00452023
Delayed-Immediate Breast Reconstruction
NCT00473122
Study of ABT-510 (Thrombospondin Analogue) in Patients With Advanced Head and Neck Cancer
NCT00113334
Oxaliplatin-Based Chemotherapy and Chemoradiotherapy or Chemoradiotherapy in Esophageal or Gastroesophageal Carcinoma
NCT00525915
Group Therapy for Nicotine Dependence: Mindfulness and Smoking
NCT00297479
Erlotinib and Docetaxel With Concomitant Boost Radiation Therapy (XRT) for Head and Neck Squamous Cell Carcinoma (HNSCC)
NCT00113347
Targeted Intervention for Melanoma Prevention
NCT00394134
FCM-R (Fludarabine, Cyclophosphamide, Mitoxantrone, Rituximab) in Previously Untreated Patients With Chronic Lymphocytic Leukemia (CLL) < 70 Years
NCT00254410
Cisplatin HAI Study in Patients With Advanced Cancer and Dominant Liver Involvement
NCT00507962
Rituximab in Addition to Autologous Transplantation With BEAM for Patients With Lymphoid Malignancies
NCT00472056
Molecular Imaging for Detection of Cervical Intraepithelial Neoplasia
NCT00511615
Autologous Transplantation for Chronic Myelogenous Leukemia
NCT01003054
Neoadjuvant Herceptin for Ductal Carcinoma In Situ of the Breast
NCT00496808
Low-Dose Decitabine in Myelodysplastic Syndrome Post Azacytidine Failure
NCT00113321
Study of Atiprimod Treatment for Patients With Advanced Cancer
NCT00430014
Neoadjuvant Chemoradiation With RHUMAB VEGF (Avastin) for Rectal Cancer
NCT00113230
Neoadjuvant Clinical Trial to Evaluate the Efficacy of Bevacizumab for Renal Cell Carcinoma
NCT00113217
External Beam Radiation Therapy (EBRT) With or Without Hormonal Therapy in Prostate Cancer
NCT00388804
4-HPR and FTI in Head and Neck Squamous Cell Carcinoma (HNSCC)
NCT00102635
Imatinib Mesylate and Docetaxel in Non-Small Cell Lung Cancer (NSCLC)
NCT01083589
RAD001 Plus Octreotide Depot in Metastatic or Unresectable Low Grade Neuroendocrine Carcinoma
NCT00113360
Non-Myeloablative Allogeneic Stem Cell Transplantation
NCT00525876
Study of FOLFIRI Plus Bevacizumab in Colorectal Cancer Patients
NCT00354978
Doxil, Gemcitabine, and Velcade (PS341) in Advanced Cancer Patients
NCT00500422
Treatment of Resectable Malignant Brain Tumors
NCT00415467
Intraperitoneal tgDCC-E1 and Intravenous Paclitaxel in Women With Platinum-Resistant Ovarian Cancer
NCT00102622
Quality of Friendships in Children With Neurofibromatosis
NCT00508235
Psychosocial Impact of Cancer-Related Female Infertility
NCT00386217
Busulfan Plus Melphalan Conditioning Regimen for Lymphoid Malignancies or Multiple Myeloma
NCT00427765
Imatinib in Combination With Dacarbazine and Capecitabine in Medullary Thyroid Carcinoma
NCT00354523
Curcumin (Diferuloylmethane Derivative) With or Without Bioperine in Patients With Multiple Myeloma
NCT00113841
Respiratory Tumor and Normal Tissue Motion
NCT00415675
Oxaliplatin, Fludarabine, Cytarabine and Rituximab in Richter's Syndrome, Refractory CLL and PLL
NCT00452374
Capecitabine and Oxaliplatin in Adenocarcinoma of the Small Bowel and Ampulla of Vater
NCT00354887
Trial of Curcumin in Advanced Pancreatic Cancer
NCT00094445
Rituximab Plus Sargramostim (GM-CSF) In Patients With Chronic Lymphocytic Leukemia
NCT00940342
Spousal Relationships and Pain in Metastatic Breast Cancer
NCT00386620
Topotecan and Gefitinib (Iressa) for Ovarian, Peritoneal, or Fallopian Tube Cancer
NCT00317772
Bone Response in Metastatic Breast Cancer Involving Bones
NCT00420433
Alemtuzumab and Pentostatin In T-cell Neoplasms
NCT00453193
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 748 |
| Phase 2 | 971 |
| Phase 3 | 96 |
| Phase 4 | 28 |
Therapeutic Areas
What is open in the M.D. Anderson Cancer Center pipeline
549 recruiting of 2,692 indexed (20% open); 1,201 completed (45%).
Phase mix: 124 late (III/IV) vs 1,719 early (I/II) (early-phase heavy).
Top condition: Hematopoietic and Lymphoid Cell Neoplasm (44 trials), 9 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page aggregates every registered trial from this sponsor, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.